Paradigm Biocapital Advisors LP AGIO — AGIOS PHARMACEUTICALS INC

Ownership history in Paradigm Biocapital Advisors LP  ·  5 quarters on record

AI Ownership Summary

Paradigm Biocapital Advisors LP reported AGIOS PHARMACEUTICALS INC (AGIO) in 5 quarterly 13F filings from 2024 Q1 through 2025 Q3. Peak portfolio weight reached 3.05% in 2025 Q3. The latest visible filing shows AGIO at 0.23% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this AGIO ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Paradigm Biocapital Advisors LP's position in AGIOS PHARMACEUTICALS INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2025 Q3

AGIO was reported at 0.23% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
3.05% in 2025 Q3

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2024 Q1 to 2025 Q3

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

AGIO stock page Paradigm Biocapital Advisors LP fund profile Paradigm Biocapital Advisors LP full holdings
How Paradigm Biocapital Advisors LP held AGIO — position size vs. price
% of Fund (quarterly)    AGIO price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 5 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2025 Q3 REDUCED 92.5% -32.3% ✅ 200,000 -2,473,555 -92.5% 0.23% $8.0M 2025-11-14 $43.65
2025 Q3 ADDED — — — 2,673,555 +1,531,044 +134.0% 3.05% $107.3M 2025-11-14 $43.65
2025 Q2 ADDED — — — 1,142,511 +866,072 +313.3% 1.62% $38.0M 2025-08-14 $36.68
2024 Q4 REDUCED 30.9% -10.8% ✅ 276,439 -123,561 -30.9% 0.32% $9.1M 2025-02-14 $33.22
2024 Q1 INITIATED — — — 400,000 — — 0.41% $11.7M 2024-05-15 $35.18

🏢 Other funds also holding AGIO

As of 2026 Q1 — sorted by position size

Lynx1 Capital Management LP 3Y 13.96% Foresite Capital Management VI LLC 3.86% MPM BioImpact LLC 3Y 3.41% Seven Fleet Capital Management LP 2.25% Exome Asset Management LLC 2.19% ARMISTICE CAPITAL, LLC 3Y 7Y 1.92% Knott David M Jr 3Y 1.87% ARMISTICE CAPITAL, LLC 3Y 7Y 1.63% Rock Springs Capital Management LP 3Y 7Y 1.59% Parkman Healthcare Partners LLC 3Y 1.41%

FAQ About Paradigm Biocapital Advisors LP and AGIO

These are the practical questions this page is built to answer before you even open the full history table.

How long has Paradigm Biocapital Advisors LP reported owning AGIO?

Paradigm Biocapital Advisors LP reported AGIO across 5 quarterly 13F filings, from 2024 Q1 through 2025 Q3.

What was the largest reported AGIO position in Paradigm Biocapital Advisors LP's portfolio?

The largest reported portfolio weight for AGIO was 3.05% in 2025 Q3.

What is the latest reported AGIO position on this page?

The most recent filing on this page is 2025 Q3, when Paradigm Biocapital Advisors LP reported 200,000 shares, equal to 0.23% of portfolio, with an estimated market value of $8.0M.

What does the chart on this AGIO ownership page compare?

The chart compares Paradigm Biocapital Advisors LP's quarterly AGIO portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did Paradigm Biocapital Advisors LP time their AGIO position?

Based on 13F filing dates vs. subsequent AGIO price moves, Paradigm Biocapital Advisors LP correctly timed 1 out of 4 reported position changes (25%). The annualised alpha on AGIO relative to SPY over the holding period was +25.1%.

← Back to Paradigm Biocapital Advisors LP Holdings